2024 World Conference on Lung Cancer (WCLC) - Posters-P1.08D.02 Survival after Salvage Treatment Following Durvalumab Consolidation in Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC)

P1.08D.02 Survival after Salvage Treatment Following Durvalumab Consolidation in Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC)

Back to course

Pdf Summary

The study investigates the outcomes of patients with locally advanced non-small cell lung cancer (LA-NSCLC) who progressed after receiving adjuvant durvalumab, a treatment shown by the PACIFIC trial to improve progression-free survival (PFS) and overall survival (OS) when administered after chemotherapy. Despite its benefits, many patients progress during or after treatment with durvalumab, yet guidelines for subsequent therapies remain uncertain.<br /><br />The study focused on 751 patients who began new systemic therapies after adjuvant durvalumab. Key findings revealed a median duration on durvalumab of 5.5 months, with disease progression and subsequent therapy initiation occurring within a median of 8.7 months from the start and 2 months from the end of durvalumab treatment. Survival outcomes were suboptimal, with a median OS of 13 months following the initiation of post-durvalumab treatments, signaling a need for more effective treatment strategies for this patient population.<br /><br />Data was derived from a de-identified database of adult patients across various therapy categories, including PD-L1 monotherapy, combination therapies involving PD-L1 and chemotherapy, chemotherapy alone, and targeted treatments. The study emphasizes the necessity for improved treatment approaches and underscores the variability in response based on different therapy regimens, with PD-L1 monotherapy and targeted treatments sometimes extending median OS beyond that seen with chemotherapy alone.<br /><br />In conclusion, this research highlights the challenges faced by LA-NSCLC patients who progress after adjuvant durvalumab, stressing the urgent need for developing more effective therapeutic strategies tailored to this subset of patients. The study’s findings are integral for guiding future clinical decision-making and shaping new treatment protocols.

Asset Subtitle

Margaret Stalker

Meta Tag

Speaker Margaret Stalker

Topic Local-Regional NSCLC

Keywords

locally advanced non-small cell lung cancer

LA-NSCLC

adjuvant durvalumab

PACIFIC trial

progression-free survival

overall survival

systemic therapies

PD-L1 monotherapy

combination therapies

treatment strategies